openPR Logo
Press release

direct/ Stem Cell Innovations, Inc. (UK) - STEM CELL INNOVATIONS MAKES THEIR HUMAN EMBRYONIC GERM CELL PLATFORM COMMERCIALLY AVAILABLE IN EUROPE

At Bio2006 Stem Cell Innovations, Inc. (SCLL.OB) announced today that the Company will commercialize their proprietary platform of human pluripotent stem cells in Europe through their newly established European R & D facility in Leiden, the Netherlands.

CEO Dr. James Kelly recently disclosed that SCI has produced multiple lines of human pluripotent stem cells. These cell lines are able to maintain their undifferentiated state and normal chromosome complement. The cells are produced without feeder layers (xenofree). The company is able to efficiently develop multiple lines, the first step in creating banks of cells that can be matched to patients in cell therapies.

To be able to serve the European market and to make the cells available to both scientists in Academia and the European Pharma and Biotech industry, SCI will produce stem cell lines in Leiden as well as in Houston, Texas.

Contact USA:
Dr. James H. Kelly, Chief Executive Officer
T +1 281 679 7900


Contact Europe:
Emmie van Halder, Business Development
M +31 6 53 202 105, T +31 70 322 8050

Ellen de Waal, PR & Corporate Communications
M +31 6 54 711 703, T +31 70 356 1534

About Stem Cell Innovations, Inc.
Stem Cell Innovations, through its wholly owned subsidiary, Amphioxus Cell Technologies, which is based in Houston, Texas, is a cell biology company. It utilizes its proprietary C3A human liver cell line in the field of drug discovery and toxicology testing and is also engaged in the development and production of its proprietary PC(TM) pluripotent stem cells. These human cell-based disease models create a platform for the discovery, testing and development of all therapeutic modalities including small molecules, cell-based therapeutics, small interfering RNAs and antibodies.

www.stemcellinnovations.com

pdf-version press release

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company´s periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the differences could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.






The announcement distributed by directnews.
The issuer is solely responsible for the content of this announcement.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release direct/ Stem Cell Innovations, Inc. (UK) - STEM CELL INNOVATIONS MAKES THEIR HUMAN EMBRYONIC GERM CELL PLATFORM COMMERCIALLY AVAILABLE IN EUROPE here

News-ID: 7728 • Views:

More Releases from Stem Cell Innovations, Inc. (UK)

direct/ Stem Cell Innovations, Inc. (UK) - Stem Cell Innovations officially open …
Leiden, The Netherlands - June 1, 2006 - Stem Cell Innovations, Inc. (SCLL.OB) announced yesterday that the Company has opened a new R&D facility to commercialise their proprietary platform of human pluripotent stem cells (PCs(TM)) in Europe. The facility is based in Leiden, the Netherlands and encompasses 1,000 m2 of state-of-the-art research laboratories. "Establishing a site in Europe is part of SCI´s strategy to become a global leading player in
direct/ Stem Cell Innovations, Inc. (UK) - Stem Cell Innovations, Inc. files pat …
CELLS MAY BE USEFUL IN THERAPIES FOR ALS, PARKINSON´S, MULTIPLE SCLEROSIS AND OTHER NEURODEGENERATIVE DISEASES. SCOTCH PLAINS, NJ - April 27, 2006 - Stem Cell Innovations, Inc. (OTCBB: SCLL) has filed a patent application protecting the differentiation of its proprietary human pluripotent stem cells (PCs) into neural progenitor cells and purified populations of motor neurons. These cells will initially be used in the Company´s core drug discovery and toxicology platform.

More Releases for Europe

Strategy Consulting Market 2025 | Analysis By Top Key Players: Booz & Co. , Rola …
Global Strategy Consulting Market 2019-2025, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. The key players covered in this study McKinsey , The Boston Consulting Group , Bain & Company , Booz & Co. , Roland Berger Europe
Influenza Vaccination Market Global Forecast 2018-25 Estimated with Top Key Play …
UpMarketResearch published an exclusive report on “Influenza Vaccination market” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 115 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. This report focuses on the Influenza Vaccination market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This
Global Strategy Consulting Market Research Report 2018-2025 | Global Key Player …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Strategy Consulting Market Size, Status and Forecast 2018-2025” which provides an outlook for current market value as well as the expected growth of Strategy Consulting during 2018-2025. The report studies the casing heads market worldwide, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, size, growth, revenue, consumption, import and export
Strategy Consulting Market Deep Insights with Core Business Strategies 2018 - Ro …
Strategy Consulting Market report provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consist of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). Global strategy consulting market size status and forecast 2025 has a vast collection of market research reports concerning the software industry, its sub-sectors, and
Wearable Heart Monitoring Devices Market 2018 To 2023 – Top Leaders Beurer Gmb …
The Worldwide Wearable Heart Monitoring Devices Market is growing at a healthy rate. The major players in this market are Medtronic (U.S.), Kinetec Products UK Ltd. (South America), Beurer GmbH (Europe), Medisana AG (Europe), Briggs Healthcare (U.S.), Polar Electro (Europe), SUUNTO (Europe), Koninklijke Philips N.V. (Europe), Garmin Ltd. (Europe) and others. The Wolrdwide Wearable Heart Monitoring devices is segmented on the basis of products, type, application, and end users. On
Surgical Equipment Market 2018 Leading Manufacturer in Europe, the Middle East & …
The Europe, the Middle East & Africa Surgical Equipment Market is expected to grow at an approximate CAGR of 6.7% during the forecast period. A surgical equipment is a designed tool or device to carry out various surgical procedures so as to modifying biological tissues and to provide access for viewing them. The surgical equipment can be designed specifically for a particular surgery or it can be used as general purpose